Due to Coronavirus, a Virtual AIDSWatch 2020 Happened This Week—and Set a Record for Number of Attendees
AIDS United quickly revised the conference when it became clear that the COVID-19 crisis would shut down the longstanding IRL version.
April 2, 2020: Physical activity vs. heart med adherence; reducing the burden of HIV emergency care; increasing smoking cessation intervention success; virologic failure following asymptomatic HIV treatment initiation.
At least one such drug still holds that promise against coronavirus, but in general there’s little precedent for the same drug blocking different viruses.
March 26, 2020: Lopinavir/ritonavir falls short against COVID-19; impact of PrEP scale-up on HIV diagnoses; long-term cost-effectiveness of various HIV interventions; disparities in virologic suppression among young people.
March 19, 2020: Mood disorders and metabolic syndrome; comorbidity burden among women living with HIV; two-year weight gain after switching to integrase; long-term adipose tissue density trends.
March 12, 2020: The impact of age on viral suppression and immunologic recovery; chronic obstructive pulmonary disease risk among older PLWHIV; sex-based differences in older men vs. women; effect of aging on drug-drug interactions.
March 5, 2020: How U=U reduces more than HIV transmission; "other" HPV strain risks post-vaccination; vitamin E for nonalcoholic steatohepatitis; HCV therapy and increased cardiovascular risk.
Long-Acting Injectable HIV Meds Just as Good as Daily Pill for Newly Diagnosed and Those Already Undetectable
Questions still remain as to when FDA will approve, and how it will be implemented.
COVID-19 will impact both the program content and attendees this year, but there are still important HIV science presentations.
Feb. 27, 2020: U=U perception vs. reality; frequency of incorrect self-reported viral load levels; how HIV transmission cluster predicts care continuum gaps; integrase inhibitor uptake and discontinuation.